PremiumRatingsAbbVie Hold Rating: Balancing Strong Immunology Growth with Challenges in Aesthetics, Neuroscience, and Oncology AbbVie reports European Commission grants marketing authorization to Rinvoq AbbVie assumed with a Neutral at Goldman Sachs PremiumThe FlyAbbVie sees FY25 adjusted EPS with expenses $11.99-$12.19, consensus $12.28 AbbVie’s Strategic Move into Obesity Treatment Boosts Buy Rating Pharmaceutical Industry Leaders Want to Delay Trump Tariffs PremiumThe FlyLargest borrow rate increases among liquid names Nvidia, Exxon, AbbVie, Uber, Adobe: Insider Moves Unveiled AbbVie put volume heavy and directionally bearish 
